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ABSTRACT
Long interspersed nuclear element 1 is an au-
tonomous non-long terminal repeat retrotransposon
that comprises ∼17% of the human genome. Its
spontaneous retrotransposition and the accumula-
tion of heritable L1 insertions can potentially re-
sult in genome instability and sporadic disorders.
Moloney leukemia virus 10 homolog (MOV10), a pu-
tative RNA helicase, has been implicated in inhibit-
ing L1 replication, although its underlying mech-
anism of action remains obscure. Moreover, the
physiological relevance of MOV10-mediated L1 reg-
ulation in human disease has not yet been exam-
ined. Using a proteomic approach, we identified
RNASEH2 as a binding partner of MOV10. We show
that MOV10 interacts with RNASEH2, and their inter-
play is crucial for restricting L1 retrotransposition.
RNASEH2 and MOV10 co-localize in the nucleus, and
RNASEH2 binds to L1 RNAs in a MOV10-dependent
manner. Small hairpin RNA-mediated depletion of
either RNASEH2A or MOV10 results in an accu-
mulation of L1-specific RNA-DNA hybrids, suggest-
ing they contribute to prevent formation of vital L1
heteroduplexes during retrotransposition. Further-
more, we show that RNASEH2-MOV10-mediated L1
restriction downregulates expression of the rheuma-
toid arthritis-associated inflammatory cytokines and
matrix-degrading proteinases in synovial cells, impli-
cating a potential causal relationship between them
and disease development in terms of disease predis-
position.
INTRODUCTION
Long interspersed nuclear element 1 (LINE-1; L1), the only
active non-long terminal repeat (LTR) transposable ele-
ment in humans, comprises ∼17% of the whole human
genome (1). L1 retrotransposition is primarily known to be
active in germline cells or embryonic stem cells during early
embryonic development, but the L1mobility in somatic and
transformed human cells is still controversial. L1 is capa-
ble of retrotransposing autonomously across the genome
through target site-primed reverse transcription (TPRT) in
an L1 ORF2p-dependent manner (2,3). L1 retrotransposi-
tion has long been considered to be a causative factor of ge-
nomic instability and diverse genetic alterations throughout
the entire human genome (4). The accumulation of herita-
ble L1 insertions can cause the evolvability of human ge-
netic disorders (5,6). Furthermore, it has been suggested
that L1-derived nucleic acids have the potential to stimu-
late a range of aberrant inflammatory responses, including
autoimmune responses. Mutations of genes that contribute
to cellular nucleic acid metabolism appear to be linked to
immunological abnormalities (7,8); however, it is less clear
how the L1-derived nucleic acids trigger aberrant immune
responses and early onset of certain autoimmune diseases.
Moloney leukemia virus 10 homolog (MOV10), a mem-
ber of the ATP-dependent RNAhelicase superfamily 1, was
first identified as a factor that prevents production of infec-
tious Moloney leukemia virus (MLV) in mice (9). MOV10
displays broad RNA binding properties and 5′ to 3′ RNA-
duplex unwinding activity (10). Interestingly, MOV10 also
inhibits replication of a number of retroviruses (11,12) and
mobility of retroelements, including LTR and non-LTR
retrotransposons in somatic cells (13–17). Considering phy-
logenetic studies (18,19), non-LTR retrotransposons are re-
garded as likely progenitors of either retroviruses or endoge-
nous retroelements. Accordingly, it is not surprising that
MOV10 is capable of inhibiting L1 retrotransposition.
MOV10 is associated with the Argonaute 2 protein
(AGO2) of the RNA-induced silencing complex that is re-
quired for miRNA-mediated gene silencing (20); however,
MOV10-mediated L1 restriction occurs independent of this
pathway (15). Furthermore, MOV10 co-localizes with L1
ORF1p in cytoplasmic processing bodies (P-bodies) (11,21)
that play a role in the storage and degradation of trans-
lationally repressed mRNAs. Therefore, MOV10 has been
implicated in facilitating sequestration of L1 ribonucleo-
proteins (RNPs) and a degradation of L1 RNAs (15). On
the other hand, several studies have highlighted diverse
functions of nuclear MOV10 (22), including suppression
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of retroelements (17). Hence, the exact mode of MOV10-
mediated L1 restriction remains uncertain.
Ribonuclease H2 (RNASEH2) is a nuclear het-
erotrimeric enzyme that hydrolyzes RNA strands of
RNA-DNA hybrids, which spontaneously form during
cellular transcription and DNA replication (23,24). Un-
like RNASEH1, RNASEH2 is capable of removing the
5′-phosphodiester bond of ribonucleotides (rNTPs) em-
bedded in DNA duplexes (25). Given that misincorporated
ribonucleotides may be the most abundant non-canonical
nucleotides present in genomic DNA, their removal by
RNASEH2 is likely critical for maintaining genomic
integrity (26). RNASEH2 has also been shown to be
contributed to human immunodeficiency virus type 1
(HIV-1) replication (27). Due in part to the scarcity of
cellular deoxyribonucleoside triphosphates (dNTPs) in
terminally differentiated macrophages (28), the HIV-1
reverse transcriptase may misincorporate ribonucleoside
triphosphates (rNTPs) into viral cDNA during HIV-1
reverse transcription. For this reason, RNASEH2 has been
considered as a positive regulator of HIV-1 replication by
eliminating misincorporated rNTPs during HIV-1 reverse
transcription (29).
Genetic alterations in any of the three subunits of the hu-
man RNASEH2 cause Aicardi-Goutie`res syndrome (30),
an autoimmune encephalopathy with similarities to con-
genital viral infections (31). A recent study has shown that
DNA-RNA immunoprecipitation (DRIP) peaks are en-
riched in L1 and LTR-containing sequences in RNASEH2-
deficient AGS fibroblasts (32). In line with this, homozy-
gotic mutations near the catalytic core of RNASEH2A
subunit also result in a substantial decrease in enzymatic
activity in mice, thereby upregulating diverse interferon-
stimulated genes and increasing L1-derived DNA levels as
seen in AGS patients (33). However, it remains unclear
whether the increase in L1 DNA is a result of L1 reac-
tivation in either AGS fibroblasts or the mice. Although
it has been most recently reported that CRISPR/Cas9-
mediated knockout of RNASEH2A leads to a substantially
reduced retrotransposition (34), the role of RNASEH2 in
L1 metabolism is thus far not fully proven.
Herein we report that RNASEH2 contributes to
MOV10-mediated L1 inhibition. RNASEH2 interacts with
MOV10 in an RNA-dependent manner, and their interplay
is essential for suppressing L1 mobility. Further biochem-
ical and microscopic analyses reveal that RNASEH2
associates with L1 RNAs in a MOV10-dependent manner,
and that L1-derived RNA-DNA hybrids preferentially
accumulate in either RNASEH2A- or MOV10-deficient
cells. These findings suggest that RNASEH2 and MOV10
are capable of inhibiting formation of L1-derived RNA-
DNA hybrids during L1 retrotransposition. Furthermore,
we show that RNASEH2-MOV10-mediated L1 regulation
limits induction of inflammatory cytokines and activa-
tion of matrix metalloproteinase 3 (MMP-3) in synovial




FLAG-haemagglutinin (HA)-tagged Moloney leukemia
virus 10 homolog (F/H-MOV10) was purchased from
Addgene (plasmid #10976) (35). HA-MOV10K530A and
RNASEH2AG37S-FLAG variants were prepared using site-
directed mutagenesis. Substitutions were confirmed by
DNA sequencing. L1-neoTET (36) was a gift fromDr. Astrid
Roy-Engel (Addgene plasmid #51284). L1-luciferase plas-
mids (pYX015, pYX017) (37) and pAD3TE1 (38) carry-
ing 24 copies of the MS2 stem-loop RNA-binding repeat
upstream of the mneoI indicator cassette were generously
provided by Dr. Wenfeng An and Dr. Aure´lien Doucet, re-
spectively. pMS2-GFP was provided by Dr. Robert Singer
and purchased through Addgene (plasmid #27121) (39).
To generate L1 ORF1p-EGFP construct, we employed
the Gateway™ cloning system (Invitrogen). L1 ORF1 was
amplified by polymerase chain reaction (PCR) from L1-
neoTET and cloned into pEGFP-N3 expression vector. For
RNA-DNA hybrid-binding retention assay, a fusion pro-
tein of the 52-residue RNA-DNA hybrid-binding domain
(HB) of RNASEH1 and enhanced green fluorescent pro-
tein (EGFP) (hereafter referred to as HB-GFP) was con-
structed, as previously described (40). The HB domain of
RNASEH1was amplified by PCR and cloned into pEGFP-
N3 expression vector.
Cells
HeLa, HEK 293T and SW982 cells were maintained in
Dulbecco’s modified Eagle’s medium (DMEM, Hyclone)
supplemented with 10% (v/v) fetal bovine serum (FBS,
HyClone), antibiotics mixture (100 units/ml, penicillin-
streptomycin, Gibco) and 1% (v/v) GlutaMAX-I (Gibco).
Cells were incubated at 37◦C under a 5% CO2 atmosphere.
LINE-1 (L1) retrotransposition assay
For neor expression cassette-based L1 retrotransposition
assays, either HeLa or SW982 cells (3 × 105 cells/ml)
were transfected with 0.2 ∼ 1 g of L1-neoTET using
Lipofectamine™ 3000 (Invitrogen) following the manufac-
turer’s instructions. If indicated, the L1 cassette was co-
transfected with either MOV10 or RNASEH2 components
(A, B and C) at a ratio of 1:1. After 48 h of incuba-
tion, the cells were trypsinized and re-seeded in 60 mm
petri-dishes at 2 ∼ 6 × 104 cells/ml, as indicated. Cells
were maintained in the presence of G418 (1 mg/ml) for
up to 14 days. Subsequently, cells were fixed and stained
with 20% ethanol-containing crystal violet solution (Sigma-
Aldrich). Colonies were countedmanually or digitally using
the OpenCFU software (41) with customized micros.
For dual luciferase-mediated retrotransposition assays,
HeLa cells (5 × 104 cells/ml) were transfected using Lipo-
fectamine™ 3000 following the manufacturer’s instructions.
Cells were co-transfected at a 1:1 ratio with the L1-luc
expression cassette (pYX017) and either MOV10 variants
or RNASEH2 components. As a negative control for the
assay, pYX015 (an inactive L1-luc construct which con-
tains loss-of-function mutations in ORF1p) was trans-
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fected, if indicated. Puromycin (Sigma-Aldrich) was added
after 24 h of incubation at a final concentration of 1 g/ml.
Cells were harvested at 4 days post-transfection, and lumi-
nescence was monitored using the Dual-Luciferase® Re-
porter Assay System (Promega) following the manufac-
turer’s instructions. L1 activity was determined as the ra-
tio of firefly to Renilla luciferase activity (Fluc/Rluc), as
previously reported (37). If indicated, the nucleoside re-
verse transcriptase inhibitor (NRTI), 2′-3′-didehydro-2′-3′-
dideoxythymidine (d4T; Stavudine), was added to a fi-
nal concentration of 50 M. Typically, cells were treated
with complete medium for 24 h prior to transfection, and
mediumwas replaced every 24∼ 48 h onward until the end-
point of each experiment.
Quantitative real-time PCR (qPCR)
Equivalent amounts of purified genomic DNA (50 ∼
100 ng) from each sample were analyzed by qPCR. For
RT (reverse transcription)-qPCR, 1 ∼ 2 g of RNA was
reverse-transcribed using the ReverTra Ace qPCR RT
Kit (TOYOBO) following the manufacturer’s instructions.
The resulting complementary DNA (cDNA) was diluted
with sterile deionized H2O (1:10). RT-qPCR reactions
were performed in TOPreal qPCR PreMIX (Enzynomics)
with 4 l of the diluted cDNA. The total reaction volume
was 20 l, and all reactions were performed in triplicate.
The PCR reactions were performed using the iCycler
iQ real-time PCR detection system (Bio-Rad). Data
were normalized according to the expression levels of
GAPDH, MDM2 and RN7SL1, as indicated. Spliced L1
insertions or RNAs were detected with primers specific
to an exon-exon junction within the firefly luciferase
gene (Fluc). qPCR analyses were performed using the








verse, 5′- TTAATAATGGCACCACGCTTC-3′), RN7SL1
(Forward, 5′-GGGCTGTAGTGCGCTATGC-3′; Re-
verse, 5′-CCCGGGAGGTCACCATATT-3′), GAPDH
(Forward, 5′-GCAAATTCCATGGCACCGT -3′; Re-




RIP was performed to analyze potential interactions be-
tween L1 RNAs and associated proteins. Cells were co-
transfected with pYX017 (L1-luc) and corresponding ex-
pression constructs at a 1:1 ratio using Lipofectamine™
3000 following to manufacturer’s instructions. Transfected
cells were cross-linked with 1% (v/v) formaldehyde in 1×
phosphate-buffered saline (PBS) for 10 min at room tem-
perature, and the reaction was quenched by the addition
of 1 M glycine pH 7.0 to a final concentration of 0.25 M
and incubated at room temperature for 5 min. Cells were
rinsed with ice-cold 1× PBS and resuspended in RIPA
buffer (50 mM Tris-HCl pH 7.5, 1% NP-40, 0.5% sodium
deoxycholate, 0.05% sodiumdodecyl sulphate (SDS), 1mM
ethylenediaminetetraacetic acid (EDTA), 150 mM NaCl, 1
mM dithiothreitol (DTT)) containing 1× cOmplete™ Pro-
tease Inhibitor Cocktail (Roche) and RNase inhibitor (En-
zynomics). Cell extracts were sonicated and centrifuged for
10 min at 9000 × g at 4◦C, and the resulting supernatant
was pre-cleared by subsequent incubation with Protein G
Sepharose (GE healthcare) at 4◦C for 1 h. The pre-cleared
supernatant was incubated with either anti-HA (Sigma-
Aldrich) or anti-FLAG-conjugated agarose beads (Sigma-
Aldrich) overnight at 4◦C. The beads were then washed
with RIPA buffer (50 mM Tris-HCl pH 7.5, 1% NP-40,
1% sodium deoxycholate, 0.1% SDS, 1 mM EDTA, 1 M
NaCl, 2 M urea) containing 1× cOmplete™ Protease In-
hibitor Cocktail. The beads were resuspended in reverse
cross-link buffer (50 mM Tris-HCl pH 7.0, 5 mM EDTA,
10 mM DTT, 1% SDS) and then incubated for 1 h at 70◦C.
The resulting immunoprecipitatedRNAswere isolatedwith
TRIzol™ reagent (Ambion) following the manufacturer’s
protocol and subjected to RT-qPCR using primers specific
to spliced Fluc cassette. The IP signal was calculated as en-
richment over input using the following equation: Ct =
2(CtInput - CtIP). The RNA enrichment results were normal-
ized to the results obtained using a control primer pair spe-
cific to RN7SL1 and quantitated using the equation, Ct
=Ctexperiment/Ctcontrol. Student’s t-test was used to assess
statistical significance.
RNA-DNA hybrid immunoprecipitation (DRIP)
DRIP was performed as described previously (42) with
the following modifications. Briefly, corresponding HeLa
cells were lysed with lysis buffer (10 mM Tris-HCl pH
8.0, 100 mM NaCl, 25 mM EDTA pH 8.0, 0.5% SDS, 10
g/ml Proteinase K (MACHEREY-NAGEL)) and incu-
bated overnight at 55◦C. If indicated, HeLa cells were trans-
fected with pYX017 (L1-luc) using Lipofectamine™ 3000
following to the manufacturer’s instructions and harvested
at 24 h or 36 h post-transfection. Total nucleic acids were
extracted using the standard phenol-chloroform extraction
method and resuspended in Tris-EDTA (TE) pH 8.0 (Am-
bion). The nucleic acids were digested with a restriction en-
zyme cocktail (20 units of EcoRI, BamHI, HindIII, BsrBI
and XhoI; New England BioLabs) overnight at 37◦C. The
digested nucleic acids were subsequently used for qPCR re-
actions. As a negative control, half of the sample was treated
with 10 units of RNase H (M0297; New England BioLabs)
overnight at 37◦C. The resulting fragmented DNA sam-
ples were isolated using the phenol-chloroform extraction
method and resuspended in TE buffer. RNA-DNA hybrids
were immunoprecipitated from total nucleic acids by adding
10 g of S9.6 antibody (ENH001; Kerafast) in IP buffer (10
mM NaPO4 pH 7.0, 140 mM NaCl, 0.05% Triton X-100)
and incubating overnight at 4◦C. Dynabeads Protein A (50
l; Invitrogen) were used to pull-down the DNA-antibody
complexes. The beads were incubated with the samples at
room temperature for 3 h and then washed three times with
IP buffer. The DNA was eluted with IP buffer and treated
Nucleic Acids Research, 2018, Vol. 46, No. 4 1915
for 1 h with 10l of proteinase K (10 g/ml) at 55◦C. Ad-
ditionally, RNase A (EN0531; Thermo Fisher Scientific)
was added and incubated with the samples for 1 h at 37◦C
to degrade RNA. Subsequently, DNA was purified follow-
ing the phenol-chloroform extract method. For DRIP-RT-
qPCR, the precipitated nucleic acidswere denatured at 98◦C
and then treated with DNase I (2270B, Takara) at 37◦C
for 1 h. The resulting RNA was isolated using TRIzol™
reagent. The relative abundances of immunoprecipitated
RNA-DNA hybrids at the indicated region were calculated
as follows: Ct = 2(CtInput – CtIP). Nucleic acid enrichment
was further normalized to a control primer pair specific to
either MDM2 or RN7SL1 and calculated using the equa-
tion, Ct = Ctexperiment/Ctcontrol. Student’s t-test was
used to assess statistical significances.
Enzyme-linked immunosorbent assay (ELISA)
SW982 cells (3 × 105 cells/ml) were co-transfected with 0.5
g of L1-neoTET and either MOV10 or RNASEH2 compo-
nents (A, B and C, respectively) at a ratio of 1:1 using Lipo-
fectamine™ 3000 following the manufacturer’s instructions.
After incubation for 72 h, the cell culture supernatant was
harvested and analyzed by ELISA to detect levels of human
IL-6 and TNF- following the manufacturer’s instructions
(Human ELISA MAX™, Biolegend).
Matrix metalloproteinase 3 (MMP-3) activity assay
SW982 cells (3 × 105 cells/ml) were co-transfected with
0.5 g of L1-neoTET expression cassette and correspond-
ing components at a ratio of 1:1 using Lipofectamine™
3000 according to the manufacturer’s recommendation. At
72 h post-transfection, the cell culture supernatant was
harvested and was analyzed for MMP-3 activity using a
fluorescence-based assay following manufacturer’s instruc-
tions (MMP-3 Activity Assay Kit, Abcam).
Statistical analysis
Statistical analyses were performed using GraphPad Prism
5 (GraphPad Software). Comparisons between two groups
were performed using two-tailed Student’s t-test. Results are
expressed as the mean ± SD, and p-values < 0.05 are con-
sidered statistically significant.
RESULTS
Identification of RNASEH2 as a MOV10-interacting factor
Considering the functions of MOV10 as a putative RNA
helicase and an L1 restriction factor, we hypothesized that
a novel effector molecule involved in RNAmetabolismmay
be required forMOV10-mediated L1 restriction. To identify
proteins that associate with MOV10 during L1 regulation,
we co-purified MOV10-interacting proteins using dual-tag
affinity purification followed by LC-MS analysis. Of note,
we identified the RNASEH2A and B peptides among the
prominent bands at∼43 kDa (Supplementary Table S1 and
Figure S1A). Thus, we hypothesized that RNASEH2 func-
tions as an effector molecule in MOV10-mediated L1 re-
striction.
To assess whether co-purified RNASEH2 is a bona fide
interacting protein with MOV10, MOV10 expression con-
struct was co-transfected with RNASEH2A, B or C to
HeLa cells. As shown in Figure 1A, RNASEH2A, a cat-
alytic core component of RNASEH2, was reproducibly co-
immunoprecipitated with MOV10 in whole cell lysates of
transfected cells. The two auxiliary subunits of RNASEH2
(B and C) were also co-purified with ectopically expressed
MOV10 (Figure 1A). However, their interaction was sub-
stantially reduced by treatment with RNase A prior to
the immunoprecipitation procedure, suggesting that these
protein-protein interactions might be dependent on RNA
binding (Figure 1A). Endogenous RNASEH2A was also
consistently associated with endogenous MOV10 (Fig-
ure 1B), indicating that the co-immunoprecipitation data
strongly supported the LC-MS results.
To verify if RNASEH2 functionally interacts with
MOV10, we performed a nuclear/cytoplasmic fractionation
experiment using HeLa cells. A higher proportion of en-
dogenous MOV10 was found in the cytoplasm than in the
nucleus. However, endogenous RNASEH2A was predomi-
nantly found in the nucleus (Figure 1C), suggesting a func-
tional association between RNASEH2 and MOV10 in the
nucleus.
Because MOV10 interacts with L1 ORF1p (15,43–
44) (Supplementary Figure S1B), we next tested whether
MOV10 functions as a molecular platform to influence
an interaction between RNASEH2 and L1 ORF1p. Small
hairpin RNA (shRNA)-mediated depletion of endogenous
MOV10 (Figure 1D) markedly decreased the association of
RNASEH2 components with L1 ORF1p, suggesting that
MOV10 mediates the interaction between RNASEH2 and
L1 ORF1p (Figure 1E). Collectively,MOV10 interacts with
RNASEH2, and it is required for the association between
RNASEH2 and L1 ORF1p.
Interplay between RNASEH2 andMOV10 is required for in-
hibition of L1 mobility
Since MOV10 controls L1 mobility through its helicase
activity (15), we next investigated whether co-purified
RNASEH2 would affect the MOV10-mediated L1 restric-
tion. As a proof-of-principle, we performed a cell-based en-
gineered L1-retrotransposition assay (3,36). The expression
cassette carried a neomycin phosphotransferase gene (neor)
within the 3′ untranslated region (UTR) in an anti-sense
orientation relative to a CMV promoter. This gene was dis-
rupted by the addition of intronic sequences. When L1 has
been successfully retrotransposed following transcription,
self-splicing, TPRT and integration across the genome, the
cells become resistant to neomycin (Figure 2A).
Upon ectopic expression of MOV10, the number of
G418-resistant colonies was markedly reduced by 4-fold
when compared to the control condition (cells transfected
with empty vector) (Figure 2B). Consistent with this, tran-
sient overexpression of either RNASEH2 or RNASEH2
in combination with MOV10 also effectively impaired L1
mobility to similar level (Figure 2B). These results demon-
strated that bothRNASEH2 andMOV10 potently suppress
L1 mobility and thereby function as negative regulators of
L1 retrotransposition.
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Figure 1. Interaction betweenRNASEH2 andMOV10 in anRNA-dependentmanner. (A) Immunoblot analysis of RNASEH2 subunits in both cell lysates
and eluates in co-immunoprecipitation experiments. Corresponding expression constructs were co-transfected into HeLa cells. At 48 h post-transfection,
the cells were harvested for the co-immunoprecipitation assays. Total cell lysates were treated with or without RNase A prior to the immunoprecipitation
procedure. GAPDH served as the loading control, and molecular weight standards are indicated in kDa. (B) Immunoblot analysis of endogenous MOV10
and RNASEH2A followed by co-immunoprecipitation with either anti-IgG or anti-MOV10 antibody. (C) Immunoblot analysis results showing levels of
endogenous MOV10 and RNASEH2A in nuclear and cytosol fractions. (D) Western blot analysis of total cell extracts prepared from shRNA-mediated
knockdown HeLa cells using anti-MOV10, anti-RNASEH2A and anti-GAPDH antibody. The knockdown efficiency of either endogenous MOV10 or
RNASEH2A was confirmed. GAPDH served as the loading control. (E) Immunoblot analysis showing levels of RNASEH2 components in either control
or MOV10-deficient HeLa cells following co-immunoprecipitation with anti-GFP antibody. GAPDH served as the loading control, and molecular weight
standards are indicated in kDa.
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Figure 2. Suppression of L1 mobility by interplay between RNASEH2 and MOV10. (A) A schematic drawing of the L1 construct and an overview of the
L1 retrotransposition assay. The L1-neoTET expression cassette is a complete retrocompetent L1 element that encodes L1 ORF1p and L1 ORF2p driven by
a CMV promoter. The L1 construct carries a retrotransposition indicator cassette near its 3′ UTR. The cassette contains the neomycin phosphotransferase
gene (neor) interrupted by a tetrahymena self-splicing intron (36) in an anti-sense orientation relative to the transcriptional orientation of the L1 element.
The intron is spliced out of the full-length L1 RNA transcript. The spliced L1 RNA is reverse-transcribed, and the resulting cDNA is integrated into the
genome. Retrotransposition of the resulting RNA leads to expression of the indicator gene, conferring G418-resistance to host cells. (B) L1 assays were
carried out following co-transfection of the indicated expression vectors with the L1-neoTET expression cassette at a ratio of 1:1 into HeLa cells. The cells
were subjected to selection for up to 14 days in the presence of G418 (1 mg/ml). Following G418 selection, G418-resistant foci were stained with crystal
violet solution. (C) L1 retrotransposition assays using L1-neoTET cassette performed in eitherMOV10- or RNASEH2A-deficient HeLa cells. (D) L1 assays
performed by co-transfection of L1-neoTET expression cassette with the indicated expression vectors at a ratio of 1:1 into RNASEH2A-depleted HeLa
cells. (E) L1 retrotransposition assays performed in MOV10-depleted HeLa cells by introduction of the indicated expression vectors and the L1-neoTET
expression cassette at a ratio of 1:1. Representative culture dishes for each condition are shown. The graph represents quantitation of the L1 assays, and the
Y-axis depicts the number of G418-resistant foci per 20,000 ∼ 60,000 cells, as indicated. Data are shown as the mean ± standard deviation (SD) of a single
experiment with three replicates. Statistical significance was determined by two-tailed Student’s t-test with the p-values indicated (ns = not significant).
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Consistent with the previous study (13), the number
of G418-resistant colonies representing a successful L1
retrotransposition dramatically increased when endoge-
nous MOV10 was depleted by shRNA-mediated knock-
down (Figure 1D and 2C). Similarly, knockdown of en-
dogenous RNASEH2A resulted in increased L1 mobility
(Figure 1D and 2C). Furthermore, simultaneous depletion
of both cellular MOV10 and RNASEH2A resulted in a
similar degree of L1 restriction that was achieved by in-
dividual knockdown of the genes (Figure 1D and 2C). In
agreement with these results, the elevated L1 retrotrans-
position rate was accompanied by a concomitant increase
in spliced L1 DNA levels in MOV10- and RNASEH2A-
deficient HeLa cells transfected with the Fluc-carrying L1
cassette (pYX017) (Supplementary Figure S2A). To verify
the specificity of our knockdown experiments by reconstitu-
tion with shRNA-resistant expression vectors (hereafter re-
ferred to asMOV10rescue orRNASEH2Arescue), the shRNA-
resistant MOV10 (MOV10rescue) was co-transfected with
L1-neoTET into HeLa cells transduced with shRNA tar-
geting MOV10 mRNA or a control (Supplementary Fig-
ure S2B). The expression of MOV10rescue markedly de-
creased the number of G418-resistant cells, suggesting that
the observed increase of L1 retrotransposition upon knock-
down of MOV10 likely reflects an on-target rather than
off-target effect of the MOV10 shRNA (Figure 2E). Sim-
ilarly, the shRNA-mediated RNASEH2A knockdown phe-
notype was rescued by ectopic expression of the shRNA-
resistant RNASEH2A (RNASEH2Arescue) in combination
with RNASEH2B and C subunits (Figure 2D and Supple-
mentary Figure S2C).
Because RNASEH2 interacts with MOV10 in an RNA-
dependent manner and restricts L1 retrotransposition,
we thus hypothesized that RNASEH2 may function to-
gether with MOV10 to prevent L1 mobility. To ad-
dress this hypothesis, we transiently co-transfected the
L1 expression cassette with the MOV10 expression vec-
tor into RNASEH2A-deficient HeLa cells. Ectopically ex-
pressed MOV10, despite its potent anti-retroelement ac-
tivity, failed to restrict L1 retrotransposition (Figure 2D)
in RNASEH2A-depleted cells. Instead, the retrotranspo-
sition efficiency was similar to that in helicase-defective
MOV10K530A-expressing cells (Figure 2D). Given the role
of RNA helicase activity in MOV10-mediated L1 control,
overexpression of MOV10K530A served as a negative con-
trol. Conversely, overexpression of RNASEH2 in cellular
MOV10-deficient cells did not affect L1 replication despite
its ability to inhibit L1mobility (Figure 2C and 2E), indicat-
ing that RNASEH2 is a negative regulator of L1 function
in a MOV10-dependent manner. The functionally defective
RNASEH2 (30) found in AGS patient (RNASEH2AG37S)
was included as a negative control. We thus concluded that
the interplay between RNASEH2 andMOV10 is crucial for
controlling L1 retrotransposition.
RNASEH2 associates with L1-derived RNAs in a MOV10-
dependent manner
To determine if both RNASEH2 and MOV10 associate
with L1-derived RNAs, especially in the nucleus, we tran-
siently co-transfected pAD3TE1 with RNASEH2 compo-
nents and MOV10 into HeLa cells. The pAD3TE1 plasmid
contains the MS2 stem loop structures in the L1 3′ UTR
(38). Thus, we employed this expression cassette to visual-
ize the asymmetric distribution and trafficking of de novo,
intercellular L1-derived RNAs. When RNASEH2 compo-
nents were co-expressed with MS2 stem loops-containing
L1 RNAs, both RNASEH2A and L1-derived RNAs were
co-localized in the nucleus (Figure 3A, upper panel). Given
that human RNASEH2 originally assembles in the cyto-
plasm and translocates to the nucleus in an RNASEH2B-
dependent manner (45), the co-localization in the nucleus
may confer its enzymatic function. MOV10 was similarly
present with L1-derived RNAs in cytoplasmic foci as well
as in the nuclei of transfected cells indicated by the white
arrow (Figure 3A, middle panel). Of note, we observed nu-
clear co-localization of RNASEH2A and MOV10 in L1-
expressing HeLa cells (Figure 3A, lower panel), indicating
that both RNASEH2 and MOV10 can associate with L1-
derived RNAs in the nucleus.
To further substantiate this conclusion, we next exam-
ined the association of individual proteins and spliced L1-
specific RNAs using RNA immunoprecipitation assays.
These results revealed a significant abundance of L1-derived
RNAs in immunoprecipitates fromMOV10-expressing cells
when compared with control cells (Figure 3B), suggest-
ing that MOV10 associates with de novo L1 RNAs. Sim-
ilarly, co-precipitated L1-derived RNAs were highly en-
riched in RNASEH2A immunoprecipitates, whereas the
signal was diminished in the control immunoprecipitation
samples where cells were transfected with empty vectors.
These results suggest an association between RNASEH2A
and spliced L1-specific RNAs (Figure 3C). Notably, the
fold change was more pronounced in cells co-expressing
RNASEH2A and MOV10, with an ∼7-fold increase (Fig-
ure 3C). These results demonstrate an association between
RNASEH2A and spliced L1-derived RNAs in a MOV10-
dependent manner. In contrast, depletion of endogenous
MOV10 resulted in a significant decrease in de novo L1
RNA abundance (Figure 3D). Taken together, these data
support the conclusion that RNASEH2 interacts with de
novo L1 RNAs in a MOV10-dependent manner.
Loss of MOV10 results in an accumulation of L1-derived
RNA-DNA hybrids
Impairment of RNA-DNA hybrid resolution has been sug-
gested to be associated with genomic instability and an ac-
cumulation of L1 DNAs in AGS patient-derived fibroblasts
(32). Using S9.6 antibody that specifically recognizes the in-
termediate A/B helical RNA-DNA duplex conformation
(46), we explored whether deficiency of MOV10 would re-
sult in accumulation of RNA-DNA hybrids.
A nuclear enrichment of the S9.6-positive foci was ob-
served in stably RNASEH2A-depleted cells (Figure 4A,
white arrowheads). The few cytoplasmic signals may be due
to mitochondrial DNA replication (47) or unusual RNA
conformations (48). Intriguingly, shRNA-mediated deple-
tion of MOV10 also led to an accumulation of the S9.6-
positive nucleolar localization signals in the nucleus (Fig-
ure 4A, white arrowheads), suggesting that endogenous
MOV10 prevents formation of RNA-DNA hybrids. In con-
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Figure 3. Association of RNASEH2 with L1 RNAs in MOV10-dependent manner. (A) Immunofluorescent confocal microscopy (including Z-stacks)
showing the subcellular distribution of L1-derived RNAs, MOV10 and RNASEH2A. HeLa cells were transfected with pAD3TE1, a plasmid expressing a
nuclear localizedMS2-GFP fusion protein. Thesemicroscopy results revealed L1RNAaccumulation in both cytoplasmic and nuclear foci by exploiting the
24 MS2-binding sites in the pAD3TE1-derived L1 RNA. For detection of MOV10 and RNASEH2A, either anti-MOV10 antibody or anti-RNASEH2A
antibody was used as a primary antibody, respectively. Green and red lines indicate corresponding points in the orthogonal planes, showing localization of
the label within the pictured cell. The scale bar represents 10 m. (B) RNA immunoprecipitation carried out in HeLa cells co-transfected with either N-
terminally HA-tagged MOV10 or N-terminally HA-tagged MOV10K530A and the L1-luc cassette (pYX017). At 48 h post-transfection, whole cell extracts
were subjected to RNA immunoprecipitation using anti-HA antibody. The RT-qPCR was carried out using primers specific to spliced Fluc cassette. The
relative abundances of the immunoprecipitated RNA are represented as fold change over the input, relative to RN7SL1 levels. (C) RNA immunoprecipita-
tion performed in HeLa cells co-expressing the indicated combinations of expression plasmids with pYX017. The anti-FLAG antibody was used for RNA
immunoprecipitation, and the resulting RNAs in the immunoprecipitates were quantified by RT-qPCR using primers specific to spliced Fluc cassette. The
relative abundances of the immunoprecipitated RNA are represented as fold change over the input, relative to RN7SL1 levels. (D) RNA immunoprecipita-
tion performed inHeLa cells co-transfected with C-terminally FLAG-taggedRNASEH2Aor C-terminally FLAG-taggedRNASEH2AG37S with pYX017.
Cell extracts were subjected to immunoprecipitation using anti-FLAG antibody. The resulting RNAs were subjected to RT-qPCR using primers specific
to spliced Fluc cassette. The relative occupancy of the resulting immunoprecipitated RNAs is represented as fold change over the input material, relative
to RN7SL1 levels. Data are presented as the mean ± SD of three independent experiments. Statistical significance was determined using the two-tailed
Student’s t-test with the p-values indicated.
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Figure 4. Accumulation of L1-derived RNA-DNA hybrids in MOV10- and RNASEH2A-deficient cells. (A) Immunofluorescence analysis of RNA-DNA
hybrids using S9.6 antibody showing the control, MOV10- and RNASEH2A-depleted cells, respectively. A merge of the two channels is shown with the
nucleus stained with DAPI. The scale bar represents 10 m. (B) A schematic comparison of DRIP-qPCR and DRIP-RT-qPCR procedure. (C) Results
of DRIP-qPCR following immunoprecipitation using the S9.6 antibody upon 36 h post-transfection with pYX017 (L1-luc). DRIP-qPCR was performed
using primers specific to the spliced Fluc region in transfected HeLa cells. The relative abundance of RNA-DNA hybrids immunoprecipitated is repre-
sented as fold change over the input material. The data were normalized to MDM2 levels. The data are represented as mean ± SD values from three
independent experiments analyzed by two-tailed Student’s t-test with p-values indicated. (D) DRIP-RT-qPCR performed in HeLa cells transfected with
pYX017 (L1-luc). Samples were harvested at 24 h post-transfection and subjected to immunoprecipitation using the S9.6 antibody. The resulting RNAs in
the immunoprecipitates were quantified by RT-qPCR using primers specific to spliced Fluc cassette. The relative occupancy of immunoprecipitated RNA
is represented as fold change over the input material. The data were normalized to RN7SL1 levels. − RT indicates the negative controls for each sample
without reverse transcriptase. Data are presented as the mean ± SD of three independent experiments and were analyzed by two-tailed Student’s t-test
with the p-value indicated. (n/a = not available). (E) L1 retrotransposition assay using L1-luc cassette (pYX017) performed in HeLa cells transfected with
corresponding siRNAs. This luciferase reporter-based L1 assay system was previously described (37). A firefly luciferase (Fluc) gene, instead of neor, is
disrupted by an intronic sequence and inserted in the 3′ UTR of L1 in an anti-sense orientation relative to the L1 genes under the control of an independent
promoter. ARenilla luciferase (Rluc) cassette is inserted in the same backbone to allow the normalization. Luciferase activity was determined as the ratio of
Fluc/Rluc. Cells treated with 50 M stavudine (d4T) served as a negative control. Data are presented as the mean ± SD of three independent experiments
and were analyzed with two-tailed Student’s t-test with the p-values indicated.
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trast, nucleoplasmic foci were rarely detected in control cells
(Figure 4A).
The RNA-DNA hybrids accumulation in eitherMOV10-
or RNASEH2A-deficient cells was also quantitated by HB-
GFP retention FACS analysis (40). As HB-GFP interacts
with heteroduplexes in the nucleus, it is retained in the nu-
cleus following permeabilization with detergent. This leads
to a significant number of GFP-positive cells, whereas cy-
toplasmic GFP is completely washed out. Similar to the in-
tense staining in the nucleolar region with the S9.6 antibody
(Figure 4A), depletion of eitherMOV10 orRNASEH2A in-
creased the number of GFP-positive cells (Supplementary
Figure S3A).
L1-derived RNA-DNA hybrids are produced as vital in-
termediates during L1 TPRT (3). To investigate whether
RNASEH2 and MOV10 prevent formation of L1-derived
heteroduplexes, we quantitated either L1-derived DNAs or
RNAs following RNA-DNA hybrid immunoprecipitation
(hereafter referred to as DRIP-qPCR) (Figure 4B). Results
from DRIP-qPCR using primers specific to spliced Fluc
cassette revealed an accumulation of L1-derived heterodu-
plexes in both RNASEH2A- and MOV10-deficient cells
(Figure 4C). This was concomitant with an increase in HB-
GFP retention by ectopic introduction of the L1-neoTET
expression cassette into either RNASEH2A- or MOV10-
depleted cells (Supplementary Figure S3B). Cells trans-
fected with the L1 expression cassette (pYX017) exhibited
a significant change in abundance of de novo L1-specific
RNAs (Figure 4D), demonstrating that both RNASEH2
and MOV10 are involved in resolving heteroduplex inter-
mediates during L1 retrotransposition.
We then sought to determine whether other proteins in-
volved in resolution of cellular RNA-DNA hybrids con-
tribute to L1 control. To examine this, we transiently
knocked-down a panel of cellular R-loop suppressors (49),
especially RNASEH1, THO complex subunit 1 (THOC1)
and a probable helicase senataxin (SETX) and performed
dual luciferase-based L1 retrotransposition assays. Most of
the R-loop suppressors did not affect L1 control (Figure
4E, Supplementary Figure S3C and S3D). Intriguingly, hu-
man RNASEH1 did not exert any inhibitory effects on L1
suppression despite its RNase H activity, suggesting that
RNASEH2 specifically recognizes L1-derived RNA-DNA
intermediates (Figure 4E). Overall, these results indicate
that RNASEH2, together with MOV10, specifically con-
tribute to prevention of L1 heteroduplex formation during
L1 retrotransposition.
Interaction ofMOV10 with L1 ORF1p andMOV10 helicase
activity are required for RNASEH2-mediated L1 restriction
RNA helicase activity of MOV10 has been implicated as a
crucial modulator of L1 mobility (15). Thus, we hypothe-
sized that the putative helicase domain is necessary for the
anti-L1 activity of MOV10. To analyze the functions of the
MOV10 domains, we constructed two truncated MOV10
variants, N-terminalMOV10 and C-terminalMOV10 (Fig-
ure 5A). Since the N-terminal domain of MOV10 is re-
quired for its interaction with the HIV-1 nucleocapsid pro-
tein (12), we first determined if MOV10 interacts with L1
ORF1p via its N-terminal domain. As shown in Figure
5B, the full-length MOV10 strongly interacted with L1
ORF1p and the N-terminal MOV10 also associated with
L1 ORF1p. However, no interaction was observed with
the C-terminal MOV10 (Figure 5B), indicating that the N-
terminal portion of MOV10 is required for its association
with L1 ORF1p.
Next, we tested interactions between the truncated
MOV10 variants and RNASEH2. Similar to their interac-
tions with L1 ORF1p, the N-terminal region of MOV10
was sufficient to interact with the catalytic subunit of
RNASEH2A (Figure 5C). However, only the full-length
MOV10 was able to interact with the auxiliary subunits of
RNASEH2 (Figure 5D and 5E), demonstrating that full-
length MOV10 is crucial for a functional interaction to
occur with both L1 ORF1p and RNASEH2. Consistent
with this, ectopic expression of the N-terminal portion of
MOV10 lacking the RNAhelicase domain completely abol-
ished its anti-L1 activity (Figure 5A). Overexpression of
either the C-terminal portion of MOV10 or the helicase-
defective MOV10 variant (MOV10K530A) also failed to con-
trol L1 mobility (Figure 5A). Taken together, these results
indicate thatMOV10mediates a functional associationwith
both L1 ORF1p and RNASEH2, and its RNA helicase ac-
tivity is required for the RNASEH2-mediated L1 suppres-
sion.
RNASEH2-MOV10-mediated L1 restriction is linked to
rheumatoid arthritis progression
To gain insight into the biological implications of L1
suppression, we sought to examine whether RNASEH2-
MOV10-mediated L1 regulation affects the progression
of L1-derived autoimmune diseases, such as rheumatoid
arthritis (RA). To test this, we performed the neor indicator-
based L1 assays using the human synovial sarcoma cell
line, SW982, which is known to express inflammatory cy-
tokines and MMPs in response to IL-1 (50). Overexpres-
sion of MOV10 led to a significant decrease in L1 mobil-
ity in SW982 cells; however, helicase-defectiveMOV10K530A
lost its ability to negatively control L1 retrotransposition
(Figure 6A). Introduction of RNASEH2 also impaired
the formation of G418-resistant foci to similar level in
MOV10-expressing cells. In contrast, the functionally de-
fective RNASEH2AG37S failed to prevent L1 retrotranspo-
sition, indicating that RNASEH2 activity is required for L1
restriction. Furthermore, the anti-L1 activity was markedly
attenuated when RNASEH2AG37S was co-expressed with
MOV10, suggesting that the interplay betweenMOV10 and
RNASEH2 is essential for inhibition of L1 retrotransposi-
tion (Figure 6A).
We next tested whether the RNASEH2-MOV10-
mediated L1 restriction would prevent activation of
synovial cells. To test the hypothesis, we measured IL-6
and TNF- levels in culture media of cells used in L1
assays. L1 activation led to significantly elevated levels of
both IL-6 (Figure 6B) and TNF- (Figure 6C) in SW982
cells, while secretion of these cytokines was markedly di-
minished by RNASEH2-MOV10-mediated L1 restriction.
However, co-expression of MOV10 with an enzymatically
inactive form of RNASEH2A did not inhibit L1 activity,
thereby increasing IL-6 (Figure 6B) and TNF- production
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Figure 5. Contribution of MOV10 as an interaction mediator between L1 ORF1p and RNASEH2 for L1 suppression. (A) (Upper panel) A schematic
drawing of MOV10 variants. (Lower panel) L1 retrotransposition assays using L1-luc cassette performed in HeLa cells co-transfected with corresponding
MOV10 variants and pYX017 at a ratio of 1:1. Treatment of d4T (50 M) served as a negative control. Data are presented as the mean ± SD of three
independent experiments and were analyzed with two-tailed Student’s t-test with the p-values indicated. (B) Immunoblot results showing the levels of
MOV10 variants in both cell lysates and eluates followed by co-immunoprecipitation. Both L1 ORF1p expression vector and the corresponding MOV10
variants were co-transfected into HeLa cells. At 48 h post-transfection, the cells were harvested for co-immunoprecipitation assays using anti-FLAG
antibody. (C–E) Western blot analyses showing levels of RNASEH2 components in HeLa cells co-transfected with indicated combinations of expression
plasmids following co-immunoprecipitation with anti-HA antibody. GAPDH served as the loading control, and molecular weight standards are indicated
in kDa.
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Figure 6. A causal relationship between L1 restriction and RA-related gene expressions. (A) L1 retrotransposition assays using L1-neoTET cassette per-
formed in synovial SW982 cells co-transfectedwith corresponding expression vectors and the L1-neoTET expression cassette at a ratio of 1:1. The transfected
cells were subjected to selection for 10 ∼ 12 days with G418 (1 mg/ml). Following selection, G418-resistant foci were stained with crystal violet solution.
Representative culture dishes for each condition are shown. Quantitation of the L1 assays was plotted. The Y-axis depicts the number of G418-resistant
foci per 40,000 cells. Data are shown as the mean ± SD from an experiment with three replicates and were analyzed by two-tailed Student’s t-test with
the p-values indicated. (B–D) Levels of inflammatory cytokines and MMP-3 activity. In parallel to L1 assay shown in (A), cell culture supernatants were
harvested at 72 h post-transfection and analyzed by enzyme-linked immunosorbent assay (ELISA) to detect (B) IL-6 and (C) TNF- levels in SW982
cells, and fluorometric immunocapture assays were performed to detect (D) MMP-3 activity. Data are presented as the mean ± SD of three independent
experiments, and statistical significance was determined using the two-tailed Student’s t-test with the p-values indicated.
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(Figure 6C). These data demonstrated that the RNASEH2-
MOV10-mediated L1 control is linked to regulation of
RA-related cytokine induction.
Activated synovial cells also express matrix-degrading
enzymes, a pathological indicator of RA. Thus, theMMP-3
activity in cell culture supernatant was monitored. MMP-
3 activity profiles displayed a causal relationship with the
RNASEH2-MOV10-mediated L1 suppression (Figure 6D),
suggesting a potential causal relationship between L1 sup-
pression and RA-related disease progression.
DISCUSSION
The function of MOV10 to inhibit L1 retrotransposition is
conserved across diverse host species (13,15). Early studies
showed thatMOV10 localizes to cytoplasmic granules. It se-
questers L1 RNPs by interacting with L1 ORF1p, thereby
facilitating L1RNAdegradation. Later, it was revealed that
MOV10 suppresses L1 mobility in the nucleus (17). How-
ever, the precise mechanism has not been fully determined.
Therefore, the elucidation of MOV10-interacting networks
could contribute to a better understanding of the cellular
functions of MOV10, particularly howMOV10 controls L1
mobility.
In the present study, we identified a novel interaction
partner of MOV10, the host protein complex RNASEH2.
RNASEH2 associates with L1-derived RNAs in aMOV10-
dependent manner, and the interplay between RNASEH2
andMOV10 is crucial for L1 suppression. Furthermore, we
have shown that the RNASEH2-MOV10-mediated L1 con-
trol inhibits expression of RA-related indicators in synovial
cells, which provided evidence of its physiological relevance.
Our results have identified a previously unknown mecha-
nism by which both RNASEH2 andMOV10 specifically in-
terfere a formation of L1-drivedRNA-DNAhybrids during
L1 retrotransposition in the nucleus (Supplementary Figure
S4).
Extrapolating from a study on MOV10-mediated retro-
viral restriction (51), MOV10 may enhance RNASEH2 ac-
tivity during L1 retrotransposition by either changing L1
RNA secondary structures or through steric hindrance. In
support of this hypothesis, the helicase-defective form of
MOV10 was unable to restrict L1 mobility (Figure 5A). It is
also plausible that the 5′ to 3′ unwinding activity ofMOV10
causes steric hindrances during L1 ORF2p-dependent re-
verse transcription. Even though an interaction between
MOV10 and L1 ORF2p was not observed in our experi-
ments (Supplementary Figure S1B), this possibility cannot
be ruled out. There may be an additive or even a synergistic
benefit for theRNASEH2-mediated resolution of L1 hybrid
intermediates during L1 retrotransposition.
Remarkably, depletion of either RNASEH2A orMOV10
leads to an increase in L1-specific RNA-DNA hybrids, in
agreement with a previous study (32). During TPRT, L1
ORF2p binds to the polyA tract of L1 RNA to bring the
RNA template to the insertion site (52) where it nicks the
genomic DNA to initiate reverse transcription in the 3′ to 5′
direction. Consistent with this, L1-specific signals were pre-
dominantly detected at the L1 3′ UTR (Figure 4C and 4D).
The predominance of 3′ UTR signal is most likely due to 5′
truncations of L1 during retrotransposition (3). The com-
plexity of L1 RNA structures may have also influenced the
DRIP-based qPCR results, becauseRNA-DNAhybrids are
often present at UTRs of genes that post-transcriptionally
control gene expressions (42).
In addition to RNASEH2, RNASEH1 is also capable of
catalyzing the cleavage of RNAs via hydrolysis; however,
it does not affect L1 restriction (Figure 4E). This suggests
that these enzymes might have different substrate specifici-
ties. Based on these results, it is possible that RNASEH2
functionality as a L1 restriction factor depends onMOV10,
which may enable RNASEH2 to recognize the characteris-
tic heteroduplexes of L1. Therefore, RNASEH2 appears to
be the primary enzyme that specifically regulates a forma-
tion of L1-derived RNA-DNA hybrids.
Since a potential role of retroelements as immunogenic
sources in autoimmune diseases has been a major interest
over the past decades (8), understanding the interplay be-
tween RNASEH2 and MOV10 in the impairment of L1
retrotransposition will expand the spectrum of their anti-L1
activity beyond the certain disease regulation. Such insights
may improve our understanding of RNASEH2-MOV10-
mediated nucleic acid pathways in the context of innate im-
munity.
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